How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator

被引:31
作者
Gandaglia, Giorgio [1 ]
van den Bergh, Roderick C. N. [3 ]
Tilki, Derya [4 ,5 ]
Fossati, Nicola [1 ]
Ost, Piet [8 ]
Surcel, Christian I. [9 ]
Sooriakumaran, Prasanna [10 ]
Tsaur, Igor [6 ]
Valerio, Massimo [11 ]
Kretschmer, Alexander [7 ]
Zaffuto, Emanuele [1 ]
Salomon, Laurent [12 ]
Montorsi, Francesco [1 ,2 ]
Graefen, Markus [4 ]
van der Poel, Henk [3 ]
de la Taille, Alexandre [12 ]
Briganti, Alberto [1 ,2 ]
Ploussard, Guillaume [12 ,13 ]
机构
[1] IRCCS Osped San Raffaele, URI, Unit Urol, Div Oncol, Milan, Italy
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[4] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[5] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[6] Univ Med Mainz, Dept Urol, Mainz, Germany
[7] Ludwig Maximilians Univ Munchen, Urol Klin & Poliklin, Campus Grosshadern, Munich, Germany
[8] Ghent Univ Hosp, Dept Radiotherapy, Ghent, Belgium
[9] Fundeni Clin Inst, Ctr Urol Surg Dialysis & Renal Transplantat, Bucharest, Romania
[10] Univ Coll London Hosp, Dept Urooncol, London, England
[11] CHU Vaudois, Dept Urol, Lausanne, Switzerland
[12] Henri Mondor Hosp, AP HP, Dept Urol, Creteil, France
[13] St Jean Languedoc Hosp, Dept Urol, Toulouse, France
关键词
misclassification; radical prostatectomy; pathological outcomes; #PCSM; #ProstateCancer; TERM OUTCOMES; FOLLOW-UP; MANAGEMENT; IMPROVE; MEN;
D O I
10.1111/bju.14391
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectivePatients and MethodsTo develop a novel tool to increase the number of patients with prostate cancer eligible for active surveillance (AS) without increasing the risk of unfavourable pathological features (i.e., misclassification) at radical prostatectomy (RP). Overall, 16049 patients with low- or intermediate-risk prostate cancer treated with RP were identified. Misclassification was defined as non-organ confined or grade group 3 disease at RP. The coefficients of a logistic regression model predicting misclassification were used to develop a risk score. We then performed a systematic analysis of different thresholds to discriminate between patients with or without unfavourable disease and we compared it to available AS criteria. ResultsConclusionsOverall, 5289 (33.0%) patients had unfavourable disease. At multivariable analyses, PSA level, clinical stage, biopsy grade group, the number of positive cores, and PSA density were associated with the risk of unfavourable disease (all P < 0.001). The Prostate Cancer Research International: Active Surveillance (PRIAS) criteria were associated with a lower risk of misclassification (13%) compared to other criteria. Overall, 3303 (20.6%) patients were eligible according to the PRIAS protocol. The adoption of an 18% threshold according to the risk score increased the proportion of eligible patients from 20.6% to 29.4% without increasing the risk of misclassification as compared to the PRIAS criteria. The use of a novel risk score for AS selection would result in an absolute increase of 10% in the number of patients eligible for this approach without increasing the risk of misclassification.
引用
收藏
页码:823 / 830
页数:8
相关论文
共 31 条
  • [1] [Anonymous], 2015, UROL ONCOL
  • [2] Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study
    Bul, Meelan
    Zhu, Xiaoye
    Valdagni, Riccardo
    Pickles, Tom
    Kakehi, Yoshiyuki
    Rannikko, Antti
    Bjartell, Anders
    van der Schoot, Deric K.
    Cornel, Erik B.
    Conti, Giario N.
    Boeve, Egbert R.
    Staerman, Frederic
    Vis-Maters, Jenneke J.
    Vergunst, Henk
    Jaspars, Joris J.
    Stroelin, Petra
    van Muilekom, Erik
    Schroder, Fritz H.
    Bangma, Chris H.
    Roobol, Monique J.
    [J]. EUROPEAN UROLOGY, 2013, 63 (04) : 597 - 603
  • [3] Trends in Management for Patients With Localized Prostate Cancer, 1990-2013
    Cooperberg, Matthew R.
    Carroll, Peter R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (01): : 80 - 82
  • [4] Active surveillance for the management of prostate cancer in a contemporary cohort
    Dall'Era, Marc A.
    Konety, Badrinath R.
    Cowan, Janet E.
    Shinohara, Katsuto
    Stauf, Frank
    Cooperberg, Matthew R.
    Meng, Maxwell V.
    Kane, Christopher J.
    Perez, Nanette
    Master, Viraj A.
    Carroll, Peter R.
    [J]. CANCER, 2008, 112 (12) : 2664 - 2670
  • [5] Active Surveillance for Prostate Cancer: A Systematic Review of the Literature
    Dall'Era, Marc A.
    Albertsen, Peter C.
    Bangma, Christopher
    Carroll, Peter R.
    Carter, H. Ballentine
    Cooperberg, Matthew R.
    Freedland, Stephen J.
    Klotz, Laurence H.
    Parker, Christopher
    Soloway, Mark S.
    [J]. EUROPEAN UROLOGY, 2012, 62 (06) : 976 - 983
  • [6] PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER
    EPSTEIN, JI
    WALSH, PC
    CARMICHAEL, M
    BRENDLER, CB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05): : 368 - 374
  • [7] A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
    Epstein, Jonathan I.
    Zelefsky, Michael J.
    Sjoberg, Daniel D.
    Nelson, Joel B.
    Egevad, Lars
    Magi-Galluzzi, Cristina
    Vickers, Andrew J.
    Parwani, Anil V.
    Reuter, Victor E.
    Fine, Samson W.
    Eastham, James A.
    Wiklund, Peter
    Han, Misop
    Reddy, Chandana A.
    Ciezki, Jay P.
    Nyberg, Tommy
    Klein, Eric A.
    [J]. EUROPEAN UROLOGY, 2016, 69 (03) : 428 - 435
  • [8] What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series
    Gandaglia, Giorgio
    Ploussard, Guillaume
    Isbarn, Hendrik
    Suardi, Nazareno
    De Visschere, Peter J. L.
    Futterer, Jurgen J.
    Ghadjar, Pirus
    Massard, Christophe
    Ost, Piet
    Sooriakumaran, Prasanna
    Surcel, Christian I.
    van den Bergh, Roderick C. N.
    Montorsi, Francesco
    Ficarra, Vincenzo
    Giannarini, Gianluca
    Briganti, Alberto
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (04) : 164.e1 - 164.e9
  • [9] Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort
    Henderson, Daniel R.
    de Souza, Nandita M.
    Thomas, Karen
    Riches, Sophie F.
    Morgan, Veronica A.
    Sohaib, Syed A.
    Dearnaley, David P.
    Parker, Christopher C.
    van As, Nicholas J.
    [J]. EUROPEAN UROLOGY, 2016, 69 (06) : 1028 - 1033
  • [10] Can nomograms improve our ability to select candidates for active surveillance for prostate cancer?
    Iremashvili, V.
    Manoharan, M.
    Parekh, D. J.
    Punnen, S.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (04) : 385 - 389